New Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis
These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.
Source: hcplive.com
Page 2 - Robert Bissonnette News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Bissonnette. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Bissonnette Today - Breaking & Trending Today
High Response Rates in Psoriasis With Oral IL-23 Inhibitor
At least 75% improvement in up to 79% of patients at 16 weeks, 90% improvement in 60%
Source: medpagetoday.com
Oral IL-23 Inhibitor Calms Moderate to Severe Psoriasis
The small-molecule oral investigational agent JNJ-77242113 at the highest dose tested was associated with reductions in psoriasis severity comparable to injectable biologic agents.
Source: medscape.com
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
/PRNewswire/ -- Johnson & Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for...
Source: prnewswire.com
LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences
MADISON, N.J.--(BUSINESS WIRE)--Jan 12, 2024--
Source: valdostadailytimes.com